Patient Experiences, Satisfaction, and Expectations with Current Systemic Lupus Erythematosus Treatment: Results of the SLE-UPDATE Survey
Authors:
Open Access
- 24 June 2021
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 8 (3) , 1189-1205
Abstract
Objectives To provide information on systemic lupus erythematosus (SLE) patients’ experiences, satisfaction, and expectations with treatments and examine the association between treatment satisfaction and patient-reported outcomes (PRO). Methods A cross-sectional, non-interventional, online survey of US adult patients with SLE was conducted in 2019. The survey consisted of 104 questions about SLE and the following PRO instruments: LupusPRO™, Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue, Work Productivity and Activity Impairment (WPAI), an 11-point Worst Pain Numerical Rating scale (NRS), and an 11-point Worst Joint Pain NRS. Results Five hundred participants (75% female, 76% White/Caucasian, mean age 42.6 ± 12.7 years, 63% with an associate degree or higher) completed the survey. Most participants were “completely” or “somewhat satisfied” with their treatments, although satisfaction rates were lower for corticosteroids (65%), immunosuppressants (71%), and anti-malarials (55%) than for belimumab (intravenous or subcutaneous) (86%) and rituximab (94%). Treatments were more often considered “burdensome” or “very burdensome” for belimumab (67%) and rituximab (63%) than for corticosteroids (48%), immunosuppressants (49%), and anti-malarials (30%). Pain and productivity assessments supported substantial impairment for the majority of participants, even those who indicated that they were completely satisfied with treatments. The treatment goals most commonly reported as “very important” were reducing fatigue, pain, and the frequency or severity of flares. Three-quarters of participants (76.6%) indicated that their physician’s goals for their therapy matched their own goals “very” or “somewhat closely.” Despite high levels of satisfaction, most participants (63.0%) indicated that their physicians had not asked about their treatment goals during the past 3 months. Conclusion SLE patients reported high rates of satisfaction with current therapies despite identifying substantial treatment burdens, residual pain, and fatigue. Reduced fatigue, pain, and flares were the most important treatment goals for these patients.Keywords
Funding Information
- Eli Lilly and Company
This publication has 32 references indexed in Scilit:
- Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Annals of the Rheumatic Diseases, 2016
- The caregiver burden in lupus: findings from UNVEIL, a national online lupus survey in the United StatesLupus, 2016
- The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online surveyRheumatology, 2013
- Disease-Specific Patient Reported Outcome Tools for Systemic Lupus ErythematosusSeminars in Arthritis and Rheumatism, 2012
- Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short‐Form McGill Pain Questionnaire (SF‐MPQ), Chronic Pain Grade Scale (CPGS), Short Form‐36 Bodily Pain Scale (SF‐36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)Arthritis Care & Research, 2011
- The role of patient attachment and working alliance on patient adherence, satisfaction, and health-related quality of life in lupus treatmentPatient Education and Counseling, 2011
- Factors influencing the health related quality of life in patients with systemic lupus erythematosus: long-term results (2001—2005) of patients in the German Lupus Erythematosus Self-Help Organization (LULA Study)Lupus, 2010
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals of the Rheumatic Diseases, 2010
- Determinants of discordance between patients and physicians in their assessment of lupus disease activity.2003
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993